[PubMed: 14631545] 214
On March 5, Novo Nordisk released the top-line results from this pivotal kidney outcomes trial: Use of semaglutide in patients with diabetic kidney disease reduced the primary outcomea composite of kidney failure, 50% decline in estimated glomerular filtration rate (eGFR), and cardiovascular (CV) or kidney deathby an impressive 24% (Figure 1)
At Affinity Whole Health , our GLP-1 weight loss programs start at $299/month with everything included: medication, provider consultations, follow-up labs, and free 2-day shipping
In the UK, the pathway to approval typically involves: Submission of a Marketing Authorisation Application (MAA) to the MHRA Scientific review of clinical trial data, including safety, efficacy, and quality data Benefit-risk assessment by MHRA experts If approved, a subsequent NICE technology appraisal to determine whether the medicine represents value for money and should be made available within the NHS The MHRA also operates an Early Access to Medicines Scheme (EAMS) , which can allow patients with life-threatening or seriously debilitating conditions to access promising unlicensed medicines before full approval
[1] [5] While rash is not among the most commonly reported side effects of Rybelsus, the Summary of Product Characteristics (SmPC) does note that hypersensitivity reactions can occur, which may include rash or urticaria (hives)
